Connect Biopharma Holdings Ltd - ADR

CNTB | $1.35 -12.34% -9.22% 0

(0.0% 1d) (6.3% 1m) (23.9% 1y) (0.0% 2d) (0.0% 3d) (-12.3% 7d) (58.37% volume)
Earnings Calendar:
Market Cap: $ 74,346,605
https://www.connectbiopharm.com
Sec Filling | Patents | 2021 employees

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

ceiling treatment brands antibody t-cell

add to watch list Paper trade email alert is off

Instil Bio Inc

TIL | $10.71 0.66% 1.12% 0

Professional, Scientific, and T...

(0.0% 1d) (-4.0% 1m) (1567.4% 1y) (0.0% 2d) (0.0% 3d) (1.1% 7d) (-34.15% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 69,656,908
https://instilbio.com
Sec Filling | Patents | 412 employees

(US) Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.

cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | News | $3.9 150

Professional, Scientific, and T...

(0.0% 1d) (-20.7% 1m) (-45.3% 1y) (0.0% 2d) (0.0% 3d) (2.6% 7d) (-63.12% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 191,648,851
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

Quoin Pharmaceuticals Ltd - ADR

QNRX | $0.66 12K

Professional, Scientific, and T...

(0.0% 1d) (-22.4% 1m) (-99.0% 1y) (0.0% 2d) (0.0% 3d) (-9.6% 7d) (224.64% volume)
Earnings Calendar:
Market Cap: $ 2,432,740
https://cellect.co
Sec Filling | Patents | 2020 employees

(IL) Cellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

ceiling t-cell

add to watch list Paper trade email alert is off